Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether potentiating the cystic fibrosis
transmembrane conductance regulator (CFTR) with QBW251 in patients with bronchiectasis will
demonstrate clinical safety and efficacy related to improved mucociliary clearance with
reduced bacterial colonization as potential drivers of airway obstruction, reduced airway
inflammation, exacerbations and mucus load, improved lung function, clinical symptoms and
quality of life to support further development in bronchiectasis.